US healthcare accreditor urges catheter review
This article was originally published in Clinica
The organisation that accredits US healthcare facilities is urging medical device manufacturers to redesign tubes and catheters in the hope of eliminating potentially dangerous tubing connections.
You may also be interested in...
US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.